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GOLD 2021 guidelines for COPD: what’s new and why
To The Editor
The Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) 2021 report dawns with an 
update to the diagnostic, preventive and thera-
peutic strategies for Chronic obstructive pulmo-
nary disease (COPD). Unlike the previous update 
[1], there are no major changes in diagnostic and 
treatment directives. There are however, nume-
rous small updates which stem from over two 
hundred new references that have been added [2]. 
Epidemiology and risk factors
COPD is the third leading cause of death with 
over three million deaths per year. This is projec-
ted to rise in the coming years due to an increase 
in risk factors, advancing age of the population 
and an improved outcome of infections and car-
diac illnesses. The risk factors have emphasized 
genetic factors, including matrix metalloprote-
inase (MMP-12), non-cigarette forms of smoking 
like cigars and hookah along with biomass fuel 
smoke exposure which is particularly relevant in 
developing countries like India.
COVID-19 and COPD
A separate chapter has been added on the 
COVID-19 pandemic, with a clear message that 
both diseases may coexist, but with worsened 
outcomes, and should be managed according 
to their individual guidelines without omitting 
any drug. Spirometry should be used only when 
requisite to make a diagnosis of COPD, or eva-
luate pulmonary function before a surgery. All 
patients undergoing spirometry should be tested 
for COVID-19. COPD patients should wear sur-
gical masks, maintain physical distancing and 
continue their medications as advised. There are 
no contraindications to the use of corticosteroids 
for COPD or its exacerbation. Nebulization must 
be avoided to prevent exposure of health-care per-
sonnel. However, if the patient is receiving long-
term nebulization, mesh nebulizers must be used 
only in areas with open windows and adequate 
ventilation. Shielding has been advocated as an 
easier alternative to ‘lockdowns’, as an effective 
preventive strategy. For electronic consultations 
of COPD patients, a checklist has been prepared 
along with precise instructions on its use. 
Diagnosis of COPD
The post-bronchodilator FEV1/FVC cut-off of 
0.7 was retained for diagnosing COPD. It was fo-
und to be more reliable and simplistic than using 
the lower limit of normal (LLN) in recent studies 
by Bhatt and colleagues [3]. The new spirometry 
criteria by the American Thoracic Society and 
European Respiratory Society (ATS/ERS) focusing 
on a one-second plateau or 15 seconds of expi-
ration, instead of 6 seconds, have been adopted. 
Spirometry was removed from the GOLD-ABCD 
assessment of COPD as it did not influence tre-
atment decisions. However, it has been realized 
that even ABCD is not good at predicting mortality 
and outcomes. As a compromise hence, using 
both classifications together are required in all 
COPD patients. The old classification has been 
modified into 1A, 1B, 1C up to 4A, 4B, 4C and 4D. 
The precise role of this modification is unclear 
at present, since current treatment decisions still 
focus on the ABCD approach. However, decisions 
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on surgical approaches like bullectomy or lung 
transplantation require spirometry.
Management of COPD
The management of COPD in primary health 
centres (PHC) has been stressed on. As per the 
World Health Organisation (WHO)’s Package for 
essential non-communicable disease intervention 
(PEN) for PHC; certain drugs like albuterol, tiotro-
pium and beclomethasone, spacers and peak flow 
meters should be present in all PHCs. A nebulizer 
and pulse oximeter should also be obtained, if 
resources permit.
The recommendations for using the inhaled 
route over the oral route, and long-acting over 
short-acting bronchodilators, have been streng-
thened by even more evidence. Citing the EMAX 
trial, the benefit of long-acting muscarinic antago-
nist/long-acting beta agonist (LAMA/LABA) com-
bination in improving lung function and clinical 
status vs either therapy alone has been pointed 
out [4]. There is a resurgent focus on triple drug 
therapy (inhaled steroid/LAMA/LABA) in view 
of the IMPACT and ETHOS trials [5, 6]. Even 
though significant evidence is lacking, it is one 
of the few interventions, besides smoking cessa-
tion, long-term oxygen therapy and lung volume 
reduction surgery, which actually demonstrates 
a trend towards mortality-benefit in the subgro-
up of COPD with severe disease and recurrent 
exacerbations. More evidence has been found in 
favor of pulmonary rehabilitation, in improving 
exercise capacity and quality of life. Palliation of 
dyspnea by acupuncture and acupressure have 
been added to measures like chest wall vibration 
and administration of opiates. 
Comorbidities
Further stress has been laid on management 
of comorbidities to improve morbidity and mor-
tality. Over 20–70% of patients have associated 
systolic or diastolic heart failure. Cardioselective 
beta-blockers must be used in these patients as 
per cardiovascular indications. The post-acute 
exacerbation phase of COPD is marked by a higher 
risk of cardiovascular events, including unstable 
angina, myocardial infarction and stroke, for up 
to one month. Risk factors associated with lung 
cancer in COPD, including: age > 55 years, > 
30 pack-years of smoking, emphysema, fixed ob-
struction, body mass index (BMI) < 25 kg/m2 and 
a family history of lung cancer have been em-
phasized.
Prevention
Vaccination with pneumococcal and influ-
enza vaccines has been suggested as per the 
prevalent guidelines. The Indian national guide-
lines recommend administering PCV-13 and 
PPSV-23 after the age of 50 years, since childhood 
vaccination with PCV-13 is not universal in India 
[7]. A new recommendation has been added in 
view of emerging evidence of two to five times 
increased risk of whooping cough (pertussis) in 
COPD. A booster dose of diphtheria, pertussis 
and tetanus has been recommended in those not 
vaccinated in adolescence according to CDC re-
commendation. E-cigarette and vaping-associated 
lung injury (EVALI) were recently attributable to 
vitamin E acetate in e-cigarettes. Currently, the 
use of e-cigarettes is discouraged. 
The path ahead
The recently emphasized biomass fuel expo-
sure-related COPD may gain greater recognition in 
the coming times. A large database has suggested 
that 65% of global COPD is non-smoking-related 
and this figure may be 80% for India. The GOLD 
stage 0 or PRISm (preserved ratio impaired spiro-
metry) is a functional phenotype of symptomatic 
emphysema without fixed obstruction that needs 
to be addressed under the GOLD guidelines. Asth-
ma-COPD overlap was earlier addressed in the 
GINA 2020 guidelines, but has failed to find 
importance in the GOLD 2021 document. There 
is limited benefit of mepolizumab or benralizu-
mab in eosinophilic COPD. However, the GOLD 
2021 acknowledges the difference to be statisti-
cally not significant and not related to severity of 
COPD or recurrent exacerbations. Impulse oscil-
lometry for diagnosis, extrafine particle inhaler 
for treatment, and prolonged pharmacological 
therapy for smoking cessation are other emerging 
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